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Abstract
Background: LRP5, a member of the low density lipoprotein receptor superfamily, regulates diverse developmental
processes in embryogenesis and maintains physiological homeostasis in adult organisms. However, how the
expression of human LRP5 gene is regulated remains unclear.
Results: In order to characterize the transcriptional regulation of human LRP5 gene, we cloned the 5’ flanking
region and evaluated its transcriptional activity in a luciferase reporter system. We demonstrated that both KLF15
and Sp1 binding sites between -72 bp and -53 bp contribute to the transcriptional activation of human LRP5
promoter. Chromatin immunoprecipitation assay demonstrated that the ubiquitous transcription factors KLF15 and
Sp1 bind to this region. Using Drosophila SL2 cells, we showed that KLF15 and Sp1 trans-activated the LRP5
promoter in a manner dependent on the presence of Sp1-binding and KLF15-binding motifs.
Conclusions: Both KLF15 and Sp1 binding sites contribute to the basal activity of human LRP5 promoter. This
study provides the first insight into the mechanisms by which transcription of human LRP5 gene is regulated.
Background
The LRP5 gene, located on human chromosome 11q13,
contains 23 exons encoding a 1615 amino acid single-
pass transmembrane receptor that belongs to the low
density lipoprotein (LDL) receptor superfamily. LRP5 is
highly conserved between species. There is 95% identity
between human and mouse LRP5 protein[1], and 40%
identity with the Drosophila orthologous gene, Arrow
[2]. Additionally, LRP5 bears 71% amino acid identity
with LRP6[3]. LRP5 contains an extracellular domain, a
membrane-spanning domain, and an intracellular
domain. The extracellular domain, located at the N-ter-
minus, consists of four EGF-receptor-like cysteine-rich
repeats with associated YWTD spacer domains and
three LDL receptor-like ligand binding domains[1].
LRP5 is expressed in multiple adult and embryonic tis-
sues, including bone, macrophages, fat, brain, heart,
liver, skin and pancreas, with strongest expression
occurring in the liver[1]. In bone, it is expressed by
osteoblasts of the endosteal and trabecular bone surfaces
but not by osteoclasts[4,5].
Shortly after the discovery of LRP5, multiple lines of
evidence indicate that the LRP5 plays an important role
in bone formation through the Wnt signaling pathway
[4,6,7]. Loss-of-function mutations in human LRP5 gene
cause the osteoporosis-pseudoglioma syndrome (OPPG),
an autosomal-recessive condition of juvenile onset char-
acterized by blindness due to aberrant vitreo-retinal vas-
cular growth and osteoporosis resulting in fractures and
deformation[4]. Gain-of-function mutation (G171V) in
the same gene, on the other hand, resulted in high bone
mass (HBM) [6-8]. Consistent with the observations in
human, bone formation and osteoblast proliferation are
decreased in Lrp5-deficient mice[5], and transgenic mice
that expressed the LRP5 G171V mutation in osteoblasts
exhibited enhanced osteoblastic activity, reduced osteo-
blast apoptosis, and a high bone mass phenotype [9].
Furthermore, independent epidemiological studies have
linked sequence variants in LRP5 gene with differences
in bone mineral density (BMD) and/or fracture risk
[10-13].
Consistent with the observation with the OPPG patients,
other diseases associated with abnormal angiogenesis or
vascularization of the eye are also associated with muta-
tions in LRP5 or its paralog LRP6 as well as proteins that
interact with the two receptors, including familial
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macular degeneration [18]. In addition to its essential role
in bone accrual and eye development, the LRP5 is also
required for normal cholesterol and glucose metabolism
[19,20]. Thus, LRP5 is a widely expressed receptor and is
critical for normal development. It regulates diverse devel-
opmental processes in embryogenesis and maintains phy-
siological homeostasis in adult organisms. Interestingly,
the most studied functions of LRP5 are related to its roles
as a co-receptor for the frizzled family of Wnt receptors.
Yadav et al recently demonstrated the existence of a novel
regulatory pathway whereby gut-derived 5-hydroxytrypta-
mine indirectly mediates the function of LRP5 in skeletal
differentiation [21].
Despite its important roles in several developmental
processes, the transcriptional regulation of LRP5
remains unclear. Information regarding the regulation of
LRP5 gene expression may help us to understand its
function and find potential new anabolic targets for con-
ditions such as osteoporosis. To this end, we cloned the
5’ flanking region and evaluated its transcriptional activ-
ity in a luciferase reporter system. We demonstrate that
both Krüppel-like factor 15(KLF15) and specificity pro-
tein 1(Sp1) binding motifs are essential for human LRP5
promoter activity.
Results
Identification of putative transcription factor binding sites
in human LRP5 promoter region
Before characterizing human LRP5 promoter, primer
extension was performed to identify the transcription
start site (TSS) of human LRP5 gene. We observed that
the TSS of human LRP5 gene was located 40 nucleo-
tides upstream of the 5’ end of the published cDNA
sequence (GenBank accession No: NM_002335), corre-
sponding to a T residue at position 114 upstream of the
ATG translation start site (Figure. 1A). In order to iden-
tify putative transcription factor binding sites, we ana-
lyzed the human LRP5 5’-flanking sequence from -2381
to +125 (relative to transcription start site) using the
programs MatInspector http://www.genomatix.de/pro-
ducts/MatInspector/ and AliBaba 2.1 http://www.gene-
regulation.com/pub/programs.html. No canonical TATA
box or CAAT-like sequences were evident. However,
several potential transcription factor binding motifs
were identified in the promoter region close to tran-
scription start site, including Sp1, KLF15, MZF, MAZ,
CDE and ZBPF (Figure. 1B).
The minimal promoter of human LRP5 gene is located
within the region -72/-53 relative to the transcription
start site
To determine the minimal region required for basal
activity of the LRP5 promoter, a series of deletion
constructs were generated, designated as pWT-2381,
pWT-1901, pWT-1594, pWT-1442, pWT-1309, pWT-
1167, pWT-1085, pWT-953 and pWT-359 based on
their variable 5’ end. U2OS and HEK293 cells, repre-
senting cells of osteoblastic and non-osteoblastic origin,
respectively, were used to evaluate the promoter activ-
ities and to determine whether there exist regulatory
elements that are specific to osteoblastic cells. Figure 2A
summarizes the results of these transfection analyses.
Maximal promoter activity was observed with the con-
struct pWT-359 in both U2OS and HEK293 cells.
When the sequence length increased up to -2381, a 50%
reduction in luciferase activities was observed, suggest-
ing the presence of negative regulatory elements
between -2381 and -359. These results indicate that the
human LRP5 proximal promoter elements are located
downstream -359 and that there are essential positive
control elements within the sequence from -359 to
+125. Similar trends were observed in U2OS cells and
HEK293 cells, suggesting that the regulatory sequences
within the region examined were not cell-specific.
To further define the sequence required for proximal
LRP5 promoter activity, a new series of deletion con-
structs were then generated by PCR, designed as pWT-
219, pWT-167, pWT-72, pWT-53 and pWT-40. The
relative luciferase activities were compared to that of
pWT-359 construct which was set as 100%. As shown
in figure 2B, no significant reduction of the reporter
activity was detected in the HEK293 and U2OS cell
lines when deletions were made between -359 and -72.
However, deletion from nucleotides -72 to -53 resulted
in 80% reduction in the promoter activity. These dele-
tion experiments indicate that the essential positive con-
trol elements for LRP5 promoter activity are located
between -72 and -53. Therefore, we decided to firstly
focus our interest on the minimal promoter of human
LRP5 gene.
The KLF15 and Sp1 binding sites between -72 and -53
contribute to human LRP5 promoter activity
The region between -72 and -53 is a GC-rich region,
containing two overlapped transcription factor binding
sites, one for KLF15 and the other for Sp1. To deter-
mine the contribution of the Sp1 and/or KLF15 sites to
the promoter activity, point mutations were introduced
into construct pWT-72 by PCR-based mutagenesis to
generate either single or double mutant reporter plas-
mids which were designated as pMT1-72, pMT2-72,
and pMT12-72, respectively (Figure. 3A). In pMT1-72,
the KLF15 motif GCGGGGGG was mutated to
GCTTTGGG, and in pMT2-72 the Sp1 motif
GGGCGGA was mutated to GGGTTGA. The double
mutant construct pMT12-72 contained mutations in
both motifs. The luciferase activities driven by the native
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HEK293 and U2OS cells. As illustrated in figure 3B,
relative to pWT-72, pMT1-72 and pMT2-72 showed
22-25% and 53-55% reduction in promoter activity,
respectively, confirming the positive regulatory role of
the KLF15 site and the Sp1 site. The luciferase activity
driven by double mutant (pMT12-72) was reduced to
11% in HEK293 and 20% in U2OS cells, the values as
observed in the construct that lacks both KLF15 and
Sp1 binding sites (pWT-53). These results indicate that
both KLF15 and Sp1 binding sites between -72 and -53
of human LRP5 promoter contribute to the basal activity
of human LRP5 transcription.
Trans-activation of human LRP5 promoter by KLF15 and
Sp1
To determine whether KLF15 and Sp1 functionally
modulate the LRP5 promoter activity, Drosophila SL2
cells, which are deficient in Sp1 and KLF15, were uti-
lized. SL2 cells were cotransfected with either the wild
type pWT-72 construct or the constructs with mutated
Sp1 and/or KLF15 binding sites along with the KLF15
or Sp1 expression plasmids. As shown in figure 3C and
3D, Sp1 and KLF15 stimulated LRP5 promoter activity
of the wild type construct. However, the mutant con-
structs were not activated by co-transfection with corre-
sponding expression constructs, pPacSp1 (Figure 3C) or
pPacKLF15 (Figure 3D), indicating that transactivation
of the LRP5 by Sp1 and KLF15 depends on the presence
of Sp1-binding and KLF15-binding motifs in the LRP5
promoter.
In vivo binding of Sp1 and KLF15 to human LRP5
promoter
To verify in vivo promoter binding by transcription fac-
tors KLF15 and Sp1, chromatin immunoprecipitation
(ChIP) was performed on HEK293 cells. The sonicated
nuclear extract was subjected to immunoprecipitation
with anti-KLF15 and anti-Sp1 antibodies, and the asso-
ciated chromatin DNA fragments were amplified with
the primer pairs flanking the KLF15 and Sp1 binding
sites as shown in figure 1B. As a negative control, a
reaction was included with antibodies against IgG. The
HSD17B5 promoter which contains both Sp1 and
KLF15 binding sites was used as a positive control [22].
As shown in figure 3E, Anti-KLF15 and anit-Sp1 antibo-
dies, but not IgG antibodies, could immunoprecipitate
the HSD17B5 promoter and LRP5 promoter in HEK293
cells. These results confirm that human LRP5 promoter
is indeed bound by Sp1 and KLF15 transcription factors
in vivo.
Discussion
In the present study, we have for the first time cloned
the human LRP5 promoter and analyzed its transcrip-
tional regulation. We demonstrated that both KLF15
Figure 1 Identification of the TSS of the LRP5 gene and the putative transcription factor binding sites in human LRP5 promoter.( A )
The transcription start site (TSS) was determined by primer extension, and the extended product is indicated by the arrow. (B) Nucleotide
sequence surrounding the 5’ end of human LRP5. The numbering of the sequence is relative to TSS. Distinct DNA binding sites for transcription
factors are indicated (underlined). The numbers above the sequence referred to the 5’ position of serial deletion constructs. The primers used in
ChIP assay are indicated in italic and bold.
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tribute to basal promoter activity of human LRP5 gene.
There are several lines of evidences. First, by generating
as e r i e so f5 ’ deletions, we show that the core promoter
is located between nucleotides -72 and -53 relative to
transcription start site. Second, changing the KLF15 and
Sp1 motifs within this region by introducing point
mutations strongly reduced LRP5 promoter activity.
Third, in Drosophila SL2 cells that lack endogenous Sp1
and KLF15, we show that expression of KLF15 and Sp1
is able to trans-activate the LRP5 promoter that contains
Sp1-binding and KLF15-binding motifs. Finally, ChIP
assay confirmed the binding of KLF15 and Sp1 to the
LRP5 promoter in vivo.
Kruppel-like factors (KLFs), a subclass of the zinc-fin-
ger family of transcriptional regulators, are critical regu-
lators of growth and differentiation in a broad range of
mammalian cell types[23,24]. Members of this gene
family have been characterized as regulators of both tis-
sue-specific and ubiquitous genes and can function as
transcriptional activators and/or repressors depending
on promoter context[24,25]. KLF15 is expressed in mul-
tiple tissues, including liver, white and brown adipose
tissues, kidney, heart, and skeletal muscle, with strongest
expression occurring in the liver and kidney[26]. KLF15
appears to be bi-functional, as it represses the Rho and
IRBP promoters [27] and the kidney-specific CLC-K1
and CLC-K2 promoters [28], but activates the GLUT4
promoter[26] and AceCs2 promoter[29]. In this study,
mutation of the KLF15 binding motif lead to a reduction
of the promoter activity in HEK293 and U2OS cells,
indicating that this motif located between -72 and -53
functions as a positive regulatory element and activates
the human LRP5 promoter.
The zinc-finger protein Sp1, which belongs to Sp
family, was identified as the major protein forming com-
plexes with oligonucleotides containing Sp1 and KLF15
binding motifs. The Sp family has 9 members containing
three conserved zinc finger DNA binding domains,
designated Sp1 to Sp9. Among them, Sp1, Sp3 and Sp4
are closely related containing two major glutamine-rich
transactivation domains that are essential for transcrip-
tion activation. They bind GC motifs to regulate the
expression of housekeeping, tissue-specific and viral
genes[30,31]. In the present study, we identified a func-
tional Sp1 binding site within the core promoter of
human LRP5 gene. Mutation of the Sp1 site decreased
the promoter activity by 53% in U2OS cells and 55% in
HEK293 cells. Expression of Sp1 stimulated LRP5 pro-
moter activity in a Sp1-binding site dependent manner.
Therefore, Sp1 binding site located between -72 and -53
contributes to activation of the LRP5 promoter.
KLF15 can directly interact with MEF2, and activates
the GLUT4 promoter in a synergetic manner[26]. Yama-
moto et al demonstrated that KLF15 in combination
with Sp1, synergistically activates the AceCS2 promoter
[29]. In human LRP5 promoter, KLF15 and Sp1 motifs
overlap. Simultaneously mutating KLF15 and Sp1 bind-
ing elements decreased the promoter activity more dra-
matically. This activation may be mediated by a
synergetic interaction between the KLF15 and Sp1 fac-
tors resulting in a combined effect on the promoter
activity.
Conclusions
Based on these data, we conclude that both KLF15 and
Sp1 binding sites located between positions -72 to -53
relative to the transcription start site play critical roles
in regulating the basal transcription of human LRP5
gene. The characterization of the human LRP5 basal
promoter represents a starting point to further unravel
the underlying molecular mechanisms that regulate
human LRP5 expression, contributing to the under-
standing of how the function of LRP5 is regulated dur-
ing bone formation and eye development.
Methods
Cell culture
Human osteosarcoma cells (U2OS) and human embryo-
nic kidney cells (HEK293) were purchased from the
American Type Culture Collection (Manassas, VA).
U2OS Cells were cultured in McCoy’s5 Am e d i u m
Figure 2 A sequence located between -72 and -53 confers
basal transcriptional activity of human LRP5 promoter. (A and
B) Serial 5’ deletion constructs were transfected into U2OS and
HEK293 cells, and the relative luciferase activity was determined. The
activity of pGL3-basic construct in A or that of pWT-359 construct in
B was arbitrarily set to 100%, and the relative luciferase activity of
the other constructs was calculated accordingly. Each bar represents
the value of mean ± SEM.
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Dulbecco’s modified Eagle’s medium (DMEM) (Gibco,
Invitrogen). All media contained 10% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 mg/ml strepto-
mycin (Gibco BRL). Cells were incubated in a humidi-
fied incubator equilibrated with 5% CO2 at 37°C.
Drosophila melanogaster Schneider cell line 2 (SL2;
ATCC No. CRL-1963) was purchased from Invitogen
(Carlsbad, CA) and maintained in Schneider’si n s e c t
medium supplemented with 10% fetal bovine serum and
2 mM L-glutamine plus 100 units/ml penicillin and100
mg/ml streptomycin, and cultured at 25°C.
RNA isolation and primer extension
When reaching 80% confluence in 75 cm
2 flasks, U2OS
cells were washed twice with ice-cold PBS and total
RNA was isolated with the use of TRIzol reagents
(Sigma-Aldrich, St. Louis, USA) according to the
manufacturer’s protocol. Any potential DNA contamina-
tion was removed by RNase-free DNase treatment. The
transcription start site of human LRP5 gene was deter-
mined by primer extension using a primer extension
system (Promega). An antisense primer (5’-
GGCGGCGCTGCCTCCATGTTGTCCG-3’), corre-
sponding to positions +107 to +131 (relative to tran-
scription start site) of human LRP5 cDNA (GenBank
accession No. NM_002335), was 5’end-labeled with [g
-
32P] ATP (3000 Ci/mmol) using T4 polynucleotide
kinase. The
32P-labeled primer of 10
6 cpm was added to
50 μg of total RNA from U2OS cells in a final volume
of 20 μl. The reverse transcription was performed with
AMV reverse transcriptase according to the manufac-
turer’s protocol. The reaction products were analyzed
on 6% polyacrylamide/7 M urea gels alongside manual
sequencing reaction of the plasmid DNA containing the
Figure 3 KLF15 and Sp1 binding sites located between -72 and -53 contribute to the basal transcriptional activity of human LRP5
promoter. (A) Schematic representation of the KLF15 and Sp1 elements. Point mutations (underlined) were introduced to change the binding
sites. (B) Constructs with native (pWT-72) or mutant KLF15 and/or Sp1 sites were transfected into HEK293 and U2OS cells, and the luciferase
activity was determined. The luciferase activity of pWT-72 was arbitrarily set to 100%, and the activities of other constructs were calculated
accordingly. (C and D) Sp1 and KLF15 transactivated the LRP5 promoter only if Sp1 and KLF15 binding sites were present. SL2 cells were
cotransfected with either wild type construct (pWT-72) or mutated constructs (pMT1-72 or pMT2-72) along with the Sp1 (3C) or KLF15 (3D)
expression constructs, and the relative luciferase activity was determined. The luciferase activity cotransfected with control vector (empty vector,
EV) was set to 100%, and the relative activity under KLF15 or Sp1 stimulation was calculated accordingly. (E) Chromatin immunoprecipitation
assay of KLF15 and Sp1 binding to human LRP5 promoter. The bindings of KLF15 and Sp1 to the human HSD17B5 promoter were used as a
positive control (upper panel). The bindings of KLF15 to the LRP5 promoter (lower right panel) and the binding of Sp1 to the LRP5 promoter
(lower left panel) were determined by ChIP using anti-KLF15 and anti-Sp1 antibodies, respectively. Anti-IgG antibodies were used as a negative
control. The associated chromatin DNA fragments were amplified with the primer pairs flanking the Sp1 and KLF15 binding sites. Chromatin
DNA input as described in the material and methods was subjected to the same PCR amplification.
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end-labeled primer.
Plasmids and Constructs
Utilizing the NCBI GenBank, we identified the genomic
sequence of human LRP5 and found a BAC clone (PR11-
149G19) containing the human LRP5 gene. We therefore
amplified the proximal 5’ region of human LRP5 (-2381
to +125 bp relative to transcription start site) by PCR
using PR11-149G19 clone as the template. The primers
(LRP5F and LRP5R) used are listed in Table 1. PCR pro-
duct was cloned into pMD18-T vector (TaKaRa), and
then subcloned into the firefly luciferase reporter vector
pGL3-basic, a promoter-less luciferase expression plas-
mid (Promega, Madison, WI), creating pWT-2381. This
construct was subsequently used as a template for the
generation of a series of 5’ unidirectional truncation
mutants by PCR using assorted sense primers with a
common antisense primer, LRP5R/HindIII (Table 1).
Mutant versions for specific binding sites were pre-
pared by PCR-based mutagenesis from pWT-72, using
the common reverse primer LRP5R/Hind III combining
with the forward primers -72MT1/MluI, -72MT2/MluI
and -72MT12/MluI, respectively (Table 1). The PCR
conditions were as follows: the samples were denatured
at 94°C for 4 min, and then 30 cycles were applied: 94°C
for 40 s, 60°C for 40 s and 72°C for 50 s, the samples
were further held at 72°C for 10 min. PCR products
were digested with KpnI (or MluI) and HindIII enzymes,
gel-purified, and ligated to the pGL3-basic vector. The
sequences of all constructs were confirmed by restric-
tion enzyme digestion and direct sequencing.
pPac, a Drosophila actin 5C promoter-driven expres-
sion vector, pPac-gal containing an Escherichia coli-
galactosidase, and pPacSp1 containing Sp1, were pro-
vided by Dr. G. Suske (Philipps-Universität Marburg,
Germany)[32]. The KLF15 coding cDNA was generated
by reverse transcription-PCR from HEK293 total RNA
with forward (5’-CGCGGATCCATGGTGGACCACT-
TACTTCCAGTGGACGAG-3’) and reverse (5’-
CCGCTCGAGTCAGTTCACGGAGCGCACG-
GAGCGGCTGCTC-3’) primers. BamHI and XhoI
restriction sites, respectively (bold), were introduced
into the primers for subcloning. The amplicons were
digested with BamHI and XhoI and inserted into the
Drosophila pPac expression vector after excision of the
Sp1 coding sequence from pPacSp1. Construct
sequences were confirmed by DNA sequencing.
Transient transfection and luciferase assay
Transient transfections were performed with the use of
Lipofectamine 2000 reagent (Invitrogen) as previously
described[33]. Briefly, U2OS and HEK293 cells were
seeded into 48-well plates at a density of 5 × 10
4 cells
per well and 4 × 10
4 cells per well, respectively, the
day before transfection. For each well of cells, 0.4 μg
of the LRP5 promoter constructs (deletion and site-
directed mutants) were co-transfected with 0.02 μgo f
Table 1 The oligonucleotide sequence of primers used in PCR
Name Sequence(5’!3’) Strand Location
LRP5F GCCTGACTGAGGAGCTGAAG sense -2381 ~ -2361
LRP5R GCTGCCTCCATGTTGTCC antisense +105 ~ +125
LRP5R/HindIII CCCAAGCTTGCTGCCTCCATGTTGTCC antisense +105 ~ +125
-1901 F/KpnI GACGGTACCAGCTACGATCACACCACTAC Sense -1901 ~ -1881
-1594 F/KpnI GACGGTACCGGCTGCCATGAGATCAGGTG Sense -1594 ~ -1574
-1442 F/KpnI GACGGTACCAGGCTGTGCTGGTAGAGCTG sense -1442 ~ -1422
-1309 F/KpnI GACGGTACCCTGTACCTTCTACCACCAGC Sense -1309 ~ -1279
-1167 F/KpnI GACGGTACCTTGGTAGCAGCTCAAGTGTC Sense -1167 ~ -1147
-1085 F/KpnI GACGGTACCTTCTTCATGGCCTGTCAATG Sense -1085 ~ -1065
-953 F/KpnI GACGGTACCAATCTGGAGGAACACACACG Sense -953 ~ -933
-359 F/KpnI GACGGTACCTGAAACTGCCTCGCTGTGTG Sense -359 ~ -339
-219 F/KpnI GACGGTACCGCCAAGCCTCCCGGAGGCAC Sense -219 ~ -199
-167 F/KpnI GACGGTACCCCGCGGGGACCTGCGCCGCT Sense -167 ~ -147
-72 F/MluI CGACGCGTGGCGGCGGGGGGCGGAGAAG Sense -72 ~ -52
-53 F/MluI CGACGCGTGCGGCGCGGCTTCCGCTCCCG Sense -53 ~ -33
-40 F/KpnI GACGGTACCCGCTCCCGCGCGCCCAGCTC Sense -40 ~ -20
-72MT1/MluI CGACGCGTGGCGGCTTTGGGCGGAGAAG Sense -72 ~ -52
-72MT2/MluI CGACGCGTGGCGGCGGGGGGTTGAGAAGCGGCG Sense -72 ~ -52
-72MT12/MluI CGACGCGTGGCGGCTTTGGGTTGAGAAGCGGCG Sense -72 ~ -52
Location: Nucleotide positions relative to the transcription start site (+1) of the human LRP5 gene.
Restriction sites are indicated in bold. The nucleotides of specific mutagenesis are indicated in italic and bold.
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for 24 hours after transfection and then harvested.
Luciferase activity was measured using the Dual-Luci-
ferase Reporter Assay System (Promega). To normalize
for transfection efficiency, the promoter activity of
each construct was expressed as the ratio of firefly
luciferase activity to Renilla luciferase activity. For
each construct, more than three independent experi-
ments with U2OS and HEK293 cells were performed
in triplicate.
For transient transfection of SL2 cells, one day prior
to transfection, cells were plated into 24-well plates at a
density of 5 × 10
5 cells/well. Cells were transfected with
0.5 μg of indicated reporter construct (pWT-72, pMT1-
72 and pMT2-72) and 0.1 μg of pPacSp1 or pPac KLF15
expression vector or empty vector pPac0 together with
pPac-b-gal vector (internal reference encoding the b-
galactosidase gene). Twenty-four hours after transfec-
tion, the cells were harvested and luciferase activity was
measured using Bright-Glo luciferase assay system (Pro-
mega) and b-galactosidase activity was measured using
Beta-Glo assay system (Promega). Luciferase activities
were normalized to b-galactosidase activity, reported as
means of three independent experiments, and each per-
formed in duplication.
Chromatin immunoprecipitation assays (ChIP)
ChIP assays were performed using an EZ-ChIP assay kit
(Upstate Biotechnologies, Millipore, MA) according to
the manufacturer’s instructions. Briefly, HEK293 cells
were treated with formaldehyde and lysed with lysis buf-
fer. The cell lysates were sonicated to generate 200-1000
bp DNA fragments, and cross-linked proteins were
immunoprecipitated by incubation with antibodies
against Sp1 (Santa Cruz, CA), KLF15 (Abcam, cam-
bridge, UK), and IgG, respectively. A DNA sample from
sonicated nuclear lysates that underwent reverse cross-
link and phenol/chloroform extraction was used as posi-
tive control (input). A DNA sample immunoprecipitated
by antibodies against IgG was used as negative control.
Immunoprecipitated DNA was detected by PCR amplifi-
cation using primer LRP5-ChIP-forward (5’-
CCGCGGGGACCTGCGCCGCT-3’) combining with
primer LRP5R. As a positive control, specific primers of
HSD17B5 promoter (5’-TTCTCCACAGACCATA-
TAAG-3’ and 5’-TTCCCTGTCACTTGTCTGACT-3’)
were designed to amplify the promoter region contain-
ing Sp1 the KLF15 binding sites [22]. PCR products
were separated on 2% agarose gel and visualized by ethi-
dium bromide staining.
Statistical analysis
The statistical significance of differences between experi-
mental groups was calculated using the Student’st e s t .
Group differences were considered significant if P <
0.05.
List of abbreviations
LRP5: low-density lipoprotein receptor related protein;
Sp1: specificity protein 1; KLF15: Krüppel-like factor 15;
ChIP: chromatin immunoprecipitation; HSD17B5:
human 17-hydroxysteroid dehydrogenase type 5 gene.
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